Call customer care on: 0333 358 0200
Dr Ruch Karunadasa

Authored on 24 January 2024 by Dr Ruch Karunadasa,

Reviewed 24 January 2024 by Dr Adeel Arshad.

Understanding GLP-1/GIP: A Guide to Dual-Action Weight Loss Treatments

What is GLP-1 / GIP

A groundbreaking treatment is making waves in the UK, offering new solution options for individuals with type 2 diabetes and obesity aiming for substantial weight reduction.

Tirzepatide stands out as a pioneering medication by targeting two specific receptors: the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptor, facilitating significant weight loss in patients.

More well-known medications like Semaglutide focus on a single receptor. This raises the question: how do Tirzepatide and Semaglutide differ and what does the targeting of receptors GIP and GLP-1 do?


What is GLP-1

GLP-1, or glucagon-like peptide-1, is a hormone integral to appetite regulation and insulin secretion. Leveraging this pathway, treatments can effectively curb hunger and enhance satiety, ultimately reducing caloric intake.


What is GIP

GIP, or glucose-dependent insulinotropic polypeptide, plays a pivotal role in blood sugar regulation and fat metabolism. It's key in encouraging fat reduction and preventing fat accumulation, positioning it as a critical component in weight management strategies.


Introducing Mounjaro: A Dual-Action Approach

Mounjaro represents a revolutionary treatment that targets both the GLP-1 and GIP pathways. This dual-action strategy not only moderates appetite but also modulates body fat utilisation. These improvements can reduce the risk of heart disease, kidney disease , forms of fatty liver disease as well as type 2 diabetes. With the synergistic effects of GLP-1 and GIP agonists, Mounjaro delivers a holistic approach to weight management.


What is best? GLP-1 Alone vs GLP-1/GIP Combination

Currently, there are no direct comparison trials published. However, when analysing clinical trials for both GLP-1/GIP treatments and GLP-1 only treatments, patients receiving GLP-1/GIP alongside diet and lifestyle changes achieved a 20.9% weight loss at 72 weeks, compared to a 14.9% weight loss at 68 weeks for those on GLP-1 only treatments.

The choice between GLP-1 alone and GLP-1/GIP combination treatments depends on individual needs and medical advice.


PrivateDoc weight loss programme

Our programme combines weight loss medication with tailored diet guides and lifestyle coaching.

  • Weight loss medication
  • Monthly meal plans
  • 12 week coaching plan
  • Private community access
  • Ongoing medical support

How it works

Get personalised care
02. Get personalised care

We'll provide you with a tailored treatment plan from a UK registered doctor

Get next day delivery
03. Get next day delivery

Receive genuine medication shipped discreetly to your door

Did you know?

Over 40% of the population has tried to lose weight at some point in the last 5 years – so you’re certainly not alone